Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760786 | 0.98 | KDM4E (0.38) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL462252 | 0.79 | TGFBR1 (0.37) | — | |
| SCHEMBL6572284 | 0.78 | MTNR1A (0.34) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL9419167 | 0.78 | TGFBR1 (0.36) | — | |
| SCHEMBL21081957 | 0.78 | TGFBR1 (0.36) | — | |
| SCHEMBL10062233 | 0.78 | MTNR1A (0.44) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL12052272 | 0.78 | KDM4E (0.38) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL5195022 | 0.77 | SLC22A6 (0.32) | SLC22A6 | |
| Ammonia Solution, Strong SCHEMBL27948392 | 0.76 | KDM4E (0.37) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL23888730 | 0.76 | TSHR (0.42) | MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | claimed |
| CN-1182837-C | Orally administrable immediate and prolonged-release Galenic form comprising absorption-promoting agent and use of this absorption-promoting agent | Ĭ��ר���ɷ�����˾ | 2005-01-05 | — | — | CN | disclosed |
| EP-1056445-B1 | ORALLY ADMINISTRABLE IMMEDIATE-RELEASE AND PROLONGED-RELEASE GALENIC FORM COMPRISING AN ABSORPTION-PROMOTING AGENT AND USE OF THIS ABSORPTION-PROMOTING AGENT | MERCK PATENT GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1410791-A1 | Orally administrable galenic form comprising metformine and an absorption-promoting agent | MERCK PATENT GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6514524-B1 | Improved absorption of hydrophilic ingredients because of particular excipients; calcium 3-acetylamino-1-propane sulfonate (calcium acamprosate); polysorbates, fatty ethers or esters of PEG, polyglycolysed glycerides | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-02-04 | — | — | US | disclosed |
| US-6426087-B1 | GALENIC FORMS; SUSTAINED RELEASE | MERCK PATENT GESELLSCHAFT MIT (DE) | 2002-07-30 | — | — | US | disclosed |
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | disclosed |